Viatris Stock Tumbles On Q4 Earnings Miss, FDA Warning Clouds 2025 Outlook

On Thursday, Viatris Inc. VTRS reported fourth-quarter 2024 sales of $3.52 billion, down 8% year over year, missing the consensus of $3.61 billion.The company reported adjusted EPS of 54 cents, missing the consensus of 57 cents.Brands’ net sales fell 10% to $2.16 billion, and Generic’s revenues decreased 5% to $1.35 billion.Also Read: CVS Health’s Aetna Files Lawsuit Against Drugmakers For Alleged Inflated Generic Drug PricesThe company generated approximately $85 million in new product revenues in the quar ...